Thorir Einarsson Long

Data availability Current approvals do not allow for the sharing of the underlying study data. However, data may be shared with other investigators pending the review of the iStopMM investigators and the Icelandic Bioethics Committee. References Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241–9. Google Scholar Rajkumar SV, Kumar S.

Abstract Light chain monoclonal gammopathy of undetermined significance (LC-MGUS) is an asymptomatic precursor of multiple myeloma (MM) and related disorders defined by abnormal free light chain (FLC) testing. Recently, revised FLC reference intervals were proposed by the iStopMM study group. We evaluated their performance in a large population-based cohort.

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance Supplement 1. eMethods. Screening for MGUS eTable 1. Central 99 Percentiles and 95% CIs for Serum Kappa FLC, Lambda FLC and the FLC Ratio for the Whole Group and Age and Sex Subgroups eTable 2. Rate of Abnormal Results in Age, Sex, and eGFR Subgroups When a Revised Reference Interval for Kappa FLC, Lambda FLC, and the FLC Ratio is Used in Persons Below and Above Age 70 Years eTable 3.